G-BA decisions from 12 May 2023
Here are the G-BA decisions from the G-BA meeting held on 12 May 2023 on the early benefit assessments of Tezpire, Adtralza
German Market Access – Simplified
Everything you need to know in one place, explained in simple terms
Here are the G-BA decisions from the G-BA meeting held on 12 May 2023 on the early benefit assessments of Tezpire, Adtralza
Here are the G-BA decisions from the G-BA meeting held on 20 April 2023 on the early benefit assessments of Ultomiris, Genvoya,
On Friday, 21 Oct 2022, the German House of Representatives has now finalized the law on the financial stabilization of statutory health
Last week, I wrote about Janssen’s withdrawal of the lung cancer drug Rybrevant (amivantamab) from the German market. Just a week later,
Despite strong opposition and critique raised by almost all stakeholders, the draft law on the financial stabilization of statutory health insurance (GKV-FinStG),